July 1 (Reuters) - Novavax Inc said on Friday it
expects to provide a COVID-19 vaccine targeting Omicron in the
fourth quarter as it accelerates development of shots to protect
against the BA.4 and BA.5 subvariants.
The U.S. FDA on Thursday recommended COVID-19 vaccine
manufacturers change the design of their booster shots beginning
this fall to include components tailored to combat the currently
dominant Omicron BA.4 and BA.5 subvariants.
Novavax expects additional preclinical data on shots
tailored against the fast-spreading Omicron subvariants in late
summer or fall.
The company's vaccine, based on an earlier strain of the
virus, has not yet been authorized in the United States and is
currently under U.S. Food and Drug Administration review.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak